Frontiers in Pharmacology (Dec 2022)
Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review
- Shuang Luo,
- Shuang Luo,
- Shuang Luo,
- Shuang Luo,
- Yu Jiang,
- Anfu Zheng,
- Anfu Zheng,
- Anfu Zheng,
- Yueshui Zhao,
- Yueshui Zhao,
- Yueshui Zhao,
- Xu Wu,
- Xu Wu,
- Xu Wu,
- Mingxing Li,
- Mingxing Li,
- Mingxing Li,
- Fukuan Du,
- Fukuan Du,
- Fukuan Du,
- Yu Chen,
- Yu Chen,
- Yu Chen,
- Shuai Deng,
- Shuai Deng,
- Shuai Deng,
- Meijuan Chen,
- Meijuan Chen,
- Meijuan Chen,
- Wanping Li,
- Wanping Li,
- Wanping Li,
- Xiaobing Li,
- Xiaobing Li,
- Xiaobing Li,
- Li Gu,
- Li Gu,
- Li Gu,
- Yuhong Sun,
- Yuhong Sun,
- Yuhong Sun,
- Zhangang Xiao,
- Zhangang Xiao,
- Jing Shen,
- Jing Shen,
- Jing Shen
Affiliations
- Shuang Luo
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Shuang Luo
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Shuang Luo
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Shuang Luo
- Department of Pharmacy, The Second People’s Hospital of Jiangyou, Mianyang, China
- Yu Jiang
- Department of Pharmacy, The People’s Hospital of Wusheng, Guang’an, China
- Anfu Zheng
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Anfu Zheng
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Anfu Zheng
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yueshui Zhao
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yueshui Zhao
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Yueshui Zhao
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Xu Wu
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xu Wu
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Xu Wu
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Mingxing Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Mingxing Li
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Mingxing Li
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Fukuan Du
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Fukuan Du
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Fukuan Du
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yu Chen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yu Chen
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Yu Chen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Shuai Deng
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Shuai Deng
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Shuai Deng
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Meijuan Chen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Meijuan Chen
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Meijuan Chen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Wanping Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Wanping Li
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Wanping Li
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Xiaobing Li
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Xiaobing Li
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Xiaobing Li
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Li Gu
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Li Gu
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Li Gu
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Yuhong Sun
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Yuhong Sun
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Yuhong Sun
- South Sichuan Institute of Translational Medicine, Luzhou, China
- Zhangang Xiao
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Zhangang Xiao
- Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China
- Jing Shen
- Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China
- Jing Shen
- Cell Therapy and Cell Drugs of Luzhou Key Laboratory, Luzhou, China
- Jing Shen
- South Sichuan Institute of Translational Medicine, Luzhou, China
- DOI
- https://doi.org/10.3389/fphar.2022.1064661
- Journal volume & issue
-
Vol. 13
Abstract
Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.
Keywords
- hypoxia-inducible factors
- breast cancer
- drug delivery systems
- tumor microenvironment
- angiogenesis
- glycolysis
